HNW
REGN icon

High Note Wealth’s Regeneron Pharmaceuticals REGN Stock Holding History

High Note Wealth’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.2K Buy
21
+2
+11% +$1.53K ﹤0.01% 303
2025
Q4 		$14.7K Sell
19
-2
-10% -$1.36K ﹤0.01% 293
2025
Q3 		$11.8K Sell
21
-9
-30% -$5.09K ﹤0.01% 297
2025
Q2 		$15.8K Buy
30
+25
+500% +$14K ﹤0.01% 261
2025
Q1 		$3.17K Sell
5
-7
-58% -$4.82K ﹤0.01% 579
2024
Q4 		$8.55K Buy
+12
New +$10.1K ﹤0.01% 314

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

High Note Wealth's REGN Position: Q1 2026 in Review

High Note Wealth increased its Regeneron Pharmaceuticals (REGN) stake by 11% in Q1 2026, buying an estimated $1.53K and bringing the position to 21 shares worth $16.2K. The position accounts for ﹤0.01% of the portfolio, ranked #303.

High Note Wealth first reported a position in REGN in Q4 2024 and has held it in 6 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • High Note Wealth held 21 shares of Regeneron Pharmaceuticals worth $16.2K as of Q1 2026.
  • High Note Wealth bought 2 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.53K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of High Note Wealth's portfolio in Q1 2026, its #303 holding.
  • High Note Wealth first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on High Note Wealth's 13F filing for Q1 2026, filed 11 May 2026.